ANAPTYSBIO, INC — Form 10-KT
Filed September 21, 2026 · analyzed by the Periodic Agent
10-KT
— Neutral
significance 28/100
What the filing says
AnaptysBio engaged Chris Murphy as CFO consultant effective May 11, 2026, under a 2-year agreement (through April 30, 2028) at $42,916.66/month base compensation, plus discretionary annual bonus up to 40%, $12,600 semi-annual health benefits, and $1.75M in RSU equity awards vesting 1/4 annually. Simultaneously, AnaptysBio subleased ~45,057 sq ft of its San Diego headquarters (Wateridge Circle) to First Tracks Biotherapeutics for the period April 21, 2026–April 4, 2028, with First Tracks having early termination rights as of December 31, 2027.
Why this rating
CFO hire is routine for biotech; consulting structure limits upside but preserves flexibility. Sublease reduces near-term occupancy cost (~9.3% of stated annual rent). No material M&A, financing, or covenant impact. Events are ordinary corporate management.
See more from September 21, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.